HelixNano
HelixNano develops mRNA therapeutics and vaccines by combining an advanced mRNA delivery platform with AI-driven design to target genetic diseases and infectious agents. The company uses synthetic biology and machine learning to design and optimize mRNA constructs and vaccine candidates, including cancer vaccines and coronavirus programs. HelixNano operates as a biotech R&D and therapeutics company (B2B biotech partnerships and clinical development) and integrates computational design with wet-lab development. Their platform targets both human and non-human biology applications and is positioned to scale preclinical and clinical programs across multiple disease areas.
HelixNano
HelixNano develops mRNA therapeutics and vaccines by combining an advanced mRNA delivery platform with AI-driven design to target genetic diseases and infectious agents. The company uses synthetic biology and machine learning to design and optimize mRNA constructs and vaccine candidates, including cancer vaccines and coronavirus programs. HelixNano operates as a biotech R&D and therapeutics company (B2B biotech partnerships and clinical development) and integrates computational design with wet-lab development. Their platform targets both human and non-human biology applications and is positioned to scale preclinical and clinical programs across multiple disease areas.
TL;DR
Headquarters: Boston, MA (5 Channel Center Street, Suite 600)
Founded: 2013
Focus: AI-driven synthetic biology for mRNA therapeutics and vaccines
Employees: ~20
Notable backers: Y Combinator, Sam Altman, Jeff Dean, Alumni Ventures
Company Overview
Problem Domain
mRNA therapeutics and vaccines; genetic disease and infectious disease interventions
Founded
2013
Industry
Biotechnology
Tech Stack
Funding Track Record
Investor Signal
“Backed by a mix of institutional and individual investors including Y Combinator, Sam Altman, Jeff Dean, Thiel Capital, Founders Fund, Alumni Ventures”